# PTGS1

## Overview
Prostaglandin-endoperoxide synthase 1 (PTGS1), also known as cyclooxygenase-1 (COX-1), is a gene that encodes a key enzyme involved in the biosynthesis of prostaglandins from arachidonic acid. The PTGS1 gene is constitutively expressed in various tissues, where it plays a crucial role in maintaining physiological homeostasis. The enzyme it encodes, COX-1, is a member of the cyclooxygenase family and functions as a homodimer, facilitating the conversion of arachidonic acid to prostaglandin H2, a precursor for other prostaglandins involved in processes such as inflammation, gastric mucosal protection, and platelet aggregation (García‐Martín2021Deep; Santulli2014Hormonal). PTGS1 is often referred to as a 'housekeeping' gene due to its stable expression and essential role in normal cellular functions, including the regulation of renal blood flow and gastrointestinal integrity (Wang2018Naproxen). The enzyme's activity is modulated by various post-translational modifications and interactions with small molecules, such as nonsteroidal anti-inflammatory drugs (NSAIDs), which can inhibit its function and have significant therapeutic implications (Karthikeyan2021Insights; PalmaBarqueros2020PTGS1).

## Structure
PTGS1, also known as cyclooxygenase-1 (COX-1), is an enzyme involved in the conversion of arachidonic acid to prostaglandins. The primary structure of PTGS1 consists of a polypeptide chain of 576 amino acids. Its secondary structure includes alpha-helices and beta-sheets, which contribute to the enzyme's stability and function. The tertiary structure of PTGS1 forms a homodimer, which is also its quaternary structure, allowing it to function effectively in its biological role. 

PTGS1 contains specific domains, including an EGF-like domain and a heme-binding site, which are crucial for its enzymatic activity. The heme-binding site is particularly important for the enzyme's catalytic function, as it facilitates the conversion of arachidonic acid to prostaglandins. Common post-translational modifications of PTGS1 include glycosylation and acetylation, which can influence the enzyme's activity and stability. These modifications are essential for the regulation of PTGS1's function in various physiological processes. 

The enzyme's structure and modifications are critical for its role in the prostanoid pathway, impacting processes such as inflammation and platelet function. Understanding the molecular structure of PTGS1 provides insights into its function and potential as a target for therapeutic interventions.

## Function
PTGS1, also known as cyclooxygenase-1 (COX-1), is an enzyme that plays a critical role in the conversion of arachidonic acid to prostaglandin H2, a precursor for various prostaglandins. These prostaglandins are involved in several physiological processes, including the maintenance of gastric mucosa, regulation of renal blood flow, and facilitation of platelet aggregation (García‐Martín2021Deep). PTGS1 is constitutively expressed in many tissues, contributing to homeostatic functions essential for normal cellular and systemic operations (Santulli2014Hormonal).

In healthy human cells, PTGS1 is involved in the biosynthesis of prostaglandins, which are lipid compounds that perform various functions, such as modulating inflammation and regulating blood flow (García‐Martín2021Deep). The enzyme is considered a 'housekeeping' isoform due to its regulatory functions in renal, gastrointestinal, and platelet activities (Wang2018Naproxen). PTGS1's activity is crucial for maintaining normal physiological functions, and its expression is typically stable across different tissues, ensuring the continuous production of prostaglandins necessary for cellular homeostasis and protection against environmental stressors (Santulli2014Hormonal).

## Clinical Significance
Mutations and alterations in the PTGS1 gene, which encodes the COX-1 enzyme, have been linked to several clinical conditions. Variants in PTGS1 are associated with NSAID-exacerbated respiratory disease (NERD), a condition characterized by hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs). Specific single nucleotide polymorphisms (SNPs) such as rs10306135 and rs5789 have been implicated in NERD, with rs10306135 increasing risk and rs5789 showing a protective effect (Ayuso2015Genetic). 

PTGS1 variants also contribute to cross-reactive hypersensitivity to NSAIDs, particularly ibuprofen. Two SNVs in the 3' UTR of PTGS1 are associated with decreased COX-1 activity, suggesting a genetic predisposition to hypersensitivity (García‐Martín2021Deep). 

A rare homozygous recessive variant in PTGS1 results in a congenital aspirin-like defect in platelet function, leading to impaired platelet aggregation and a bleeding phenotype. This variant causes a lack of COX-1 derived prostanoids, such as PGE2 and TXB2, in platelets (Chan2020Identification). 

These findings highlight the clinical significance of PTGS1 genetic variations in drug hypersensitivity and platelet function disorders, underscoring the importance of genetic testing in affected individuals.

## Interactions
Prostaglandin-endoperoxide synthase 1 (PTGS1), also known as cyclooxygenase-1 (COX-1), is involved in various protein interactions that are crucial for its function in prostaglandin synthesis. PTGS1 forms a homodimer and interacts with membrane proteins, which is essential for its localization and function within the dense tubular membrane system of platelets (PalmaBarqueros2020PTGS1). The enzyme's activity is modulated by post-translational modifications such as N-glycosylation, which affects its stability and function, as demonstrated by a novel genetic variant that disrupts this modification, leading to impaired platelet function (Palma‐Barqueros2021A).

PTGS1 also engages in interactions with small molecules, such as nonsteroidal anti-inflammatory drugs (NSAIDs) like aspirin, which inhibit its activity by acetylating a serine residue, thereby preventing the conversion of arachidonic acid to thromboxane A2, a key prothrombotic agent (PalmaBarqueros2020PTGS1). Molecular docking studies have shown that PTGS1 can form stable complexes with certain drugs, involving hydrogen bonds and hydrophobic interactions, which contribute to its binding affinity and stability (Karthikeyan2021Insights). These interactions highlight the enzyme's role in both physiological processes and therapeutic contexts, particularly in the management of cardiovascular diseases.


## References


[1. (PalmaBarqueros2020PTGS1) Verónica Palma-Barqueros, Natalia Bohdan, Nuria Revilla, Vicente Vicente, José M. Bastida, and José Rivera. Ptgs1 gene variations associated with bleeding and platelet dysfunction. Platelets, 32(5):710–716, June 2020. URL: http://dx.doi.org/10.1080/09537104.2020.1782370, doi:10.1080/09537104.2020.1782370. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.1080/09537104.2020.1782370)

[2. (García‐Martín2021Deep) Elena García‐Martín, Jesús M. García‐Menaya, Gara Esguevillas, José A. Cornejo‐García, Inmaculada Doña, Raquel Jurado‐Escobar, María J. Torres, Natalia Blanca‐López, Gabriela Canto, Miguel Blanca, José J. Laguna, Joan Bartra, Ana Rosado, Javier Fernández, Concepción Cordobés, and José A.G. Agúndez. Deep sequencing of prostaglandin‐endoperoxide synthase (ptge) genes reveals genetic susceptibility for cross‐reactive hypersensitivity to nsaid. British Journal of Pharmacology, 178(5):1218–1233, February 2021. URL: http://dx.doi.org/10.1111/bph.15366, doi:10.1111/bph.15366. This article has 8 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1111/bph.15366)

[3. (Chan2020Identification) Melissa V. Chan, Melissa A. Hayman, Suthesh Sivapalaratnam, Marilena Crescente, Harriet E. Allan, Matthew L. Edin, Darryl C. Zeldin, Ginger L. Milne, Jonathan Stephens, Daniel Greene, Moghees Hanif, Valerie B. O’Donnell, Liang Dong, Michael G. Malkowski, Claire Lentaigne, Katherine Wedderburn, Matthew Stubbs, Kate Downes, Willem H. Ouwehand, Ernest Turro, NIHR BioResource, Daniel P. Hart, Kathleen Freson, Michael A. Laffan, and Timothy D. Warner. Identification of a homozygous recessive variant in &lt;i&gt;ptgs1&lt;/i&gt; resulting in a congenital aspirin-like defect in platelet function. Haematologica, 106(5):1423–1432, April 2020. URL: http://dx.doi.org/10.3324/haematol.2019.235895, doi:10.3324/haematol.2019.235895. This article has 7 citations.](https://doi.org/10.3324/haematol.2019.235895)

[4. (Karthikeyan2021Insights) Subramani Karthikeyan, Xiaoyi Yue, Alexey A. Festa, and Leonid G. Voskressensky. Insights into the binding interaction mechanism of 12,12-dihydrochromeno[2,3-c]isoquinolin-5-amine in bovine serum albumin and prostaglandin h2 synthase-1: a biophysical approach. Journal of Molecular Structure, 1245:131131, December 2021. URL: http://dx.doi.org/10.1016/j.molstruc.2021.131131, doi:10.1016/j.molstruc.2021.131131. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.molstruc.2021.131131)

[5. (Wang2018Naproxen) Cuijiang Wang, Fei Wang, Fen Lin, Xiaohong Duan, and Binna Bi. Naproxen attenuates osteoarthritis progression through inhibiting the expression of prostaglandinl‐endoperoxide synthase 1. Journal of Cellular Physiology, 234(8):12771–12785, December 2018. URL: http://dx.doi.org/10.1002/jcp.27897, doi:10.1002/jcp.27897. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/jcp.27897)

[6. (Ayuso2015Genetic) Pedro Ayuso, María del Carmen Plaza-Serón, Natalia Blanca-López, Inmaculada Doña, Paloma Campo, Gabriela Canto, José Julio Laguna, Joan Bartra, Victor Soriano-Gomis, Miguel Blanca, José A Cornejo-García, and James R Perkins. Genetic variants in arachidonic acid pathway genes associated with nsaid-exacerbated respiratory disease. Pharmacogenomics, 16(8):825–839, June 2015. URL: http://dx.doi.org/10.2217/pgs.15.43, doi:10.2217/pgs.15.43. This article has 19 citations and is from a peer-reviewed journal.](https://doi.org/10.2217/pgs.15.43)

[7. (Palma‐Barqueros2021A) Verónica Palma‐Barqueros, Marilena Crescente, María Eugenia de la Morena, Melissa V. Chan, Elena Almarza, Nuria Revilla, Natalia Bohdan, Antonia Miñano, José Padilla, Harriet E. Allan, Tania Maffucci, Matthew L. Edin, Darryl C. Zeldin, Cristina Mesa‐Nuñez, Carlos Damian, Ana Marín‐Quilez, Rocío Benito, Irene Martínez‐Martínez, Nuria Bermejo, Ignacio Casas‐Aviles, Agustín Rodríguez‐Alen, José R. González‐Porras, Jesús María Hernández‐Rivas, Vicente Vicente, Javier Corral, María L. Lozano, Timothy D. Warner, José María Bastida, and José Rivera. A novel genetic variant in <scp>ptgs1</scp> affects n‐glycosylation of cyclooxygenase‐1 causing a dominant‐negative effect on platelet function and bleeding diathesis. American Journal of Hematology, January 2021. URL: http://dx.doi.org/10.1002/ajh.26076, doi:10.1002/ajh.26076. This article has 1 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/ajh.26076)

[8. (Santulli2014Hormonal) Pietro Santulli, Bruno Borghese, Jean-Christophe Noël, Isabelle Fayt, Vincent Anaf, Dominique de Ziegler, Frederic Batteux, Daniel Vaiman, and Charles Chapron. Hormonal therapy deregulates prostaglandin-endoperoxidase synthase 2 (ptgs2) expression in endometriotic tissues. The Journal of Clinical Endocrinology &amp; Metabolism, 99(3):881–890, March 2014. URL: http://dx.doi.org/10.1210/jc.2013-2950, doi:10.1210/jc.2013-2950. This article has 42 citations.](https://doi.org/10.1210/jc.2013-2950)